A Comparative Assessment Study of Known Small-molecule GPVI Modulators (original) (raw)
Foster, H, Wilson, C, Gauer, JS orcid.org/0000-0002-0835-639X et al. (8 more authors) (2022)A Comparative Assessment Study of Known Small-molecule GPVI Modulators. ACS Medicinal Chemistry Letters, 13 (2). pp. 171-181. ISSN 1948-5875
Abstract
The GPVI platelet receptor was recently validated as a safe antiplatelet target for the treatment of thrombosis using several peptidic modulators. In contrast, few weakly potent small-molecule GPVI antagonists have been reported. Those that have been published often lack evidence for target engagement, and their biological efficacy cannot be compared because of the natural donor variability associated with the assays implemented. Herein, we present the first side-by-side assessment of the reported GPVI small-molecule modulators. We have characterized their functional activities on platelet activation and aggregation using flow cytometry as well as light transmission and electrical impedance aggregometry. We also utilized microscale thermophoresis (MST) and saturation transfer difference (STD) NMR to validate GPVI binding and have used this along with molecular modeling to suggest potential binding interactions. We conclude that of the compounds examined, losartan and compound 5 are currently the most viable GPVI modulators.
